In Vivo Tumor Secretion Probing Via Ultrafiltration and Tissue Chamber:Implication for Anti-Cancer Drugs Targeting Secretome

Author(s): Chun-Ming Huang, Teruaki Nakatsuji, Yu-Tseung Liu, Yang Shi

Journal Name: Recent Patents on Anti-Cancer Drug Discovery

Volume 3 , Issue 1 , 2008

Become EABM
Become Reviewer
Call for Editor


Tumor secreted proteins/peptides (tumor secretome) act as mediators of tumor-host communication in the tumor microenvironment. Therefore, development of anti-cancer drugs targeting secretome may effectively control tumor progression. Novel techniques including a capillary ultrafiltration (CUF) probe and a dermis-based cell-trapped system (DBCTS) linked to a tissue chamber were utilized to sample in vivo secretome from tumor masses and microenvironments. The CUF probe and tissue chamber were evaluated in the context of in vivo secretome sampling. Both techniques have been successfully integrated with mass spectrometry for secretome identification. A secretome containing multiple proteins and peptides can be analyzed by NanoLC-LTQ mass spectrometry, which is specially suited to identifying proteins in a complex mixture. In the future, the establishment of comprehensive proteomes of various host and tumor cells, as well as plasma will help in distinguishing the cellular sources of secretome. Many detection methods have been patented regarding probes and peptide used for identification of tumors.

Keywords: Tumor secretion, ultrafiltration, secretome, drugs, mass spectrometry, tissue chamber

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2008
Published on: 01 March, 2012
Page: [48 - 54]
Pages: 7
DOI: 10.2174/157489208783478694

Article Metrics

PDF: 19